AAHRPP, ViS Research Institute collaborate

Wednesday, June 26, 2013 02:51 PM

The Association for the Accreditation of Human Research Protection Programs (AAHRPP) and the ViS Research Institute have allied to protect research participants by providing easy access to information on the quality and standards of organizations that conduct clinical trials.

ViS has developed an online analytics platform to streamline the feasibility assessment of research sites. ViS profiles of research sites will now include information on whether the site has earned AAHRPP accreditation—an objective measure of research quality, ethics and protections.

“AAHRPP and ViS are streamlining the site selection process, making it easier for research sponsors and CROs to identify sites that have committed to high standards,” said Marjorie Speers, Ph.D., AAHRPP president and chief executive officer. “We are confident that, if information on quality is readily available, it will play a key role in decisions on where to conduct clinical trials.”

Research sites earn accreditation by demonstrating that their human research protection programs adhere to AAHRPP standards and by committing to continuous quality improvement. More than 180 organizations worldwide—including over 60% of U.S. research-intensive universities and U.S. teaching hospitals—are accredited. They represent over 600 research entities.

The alliance will increase visibility with research sponsors, CROs and other trial planners and reduce the time and costs of fulfilling multiple requests for information. Instead of responding separately to feasibility questionnaires, organizations can provide information online in a ViS profile.

“The alliance between ViS and AAHRPP will enhance the efficiency and quality of clinical trial planning,” said Fabio Thiers, M.D., Ph.D., chief executive officer of ViS, “and will contribute to improved research participant protection and to the accelerated development of needed medicines.”

Share:          
CWWeekly

February 23

Venture capital investors funding novel drug R&D three times more than companies repurposing, improving existing drugs

In appreciation: Karen Woodin will be remembered for her teaching, writing and lasting friendships

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs